Livzon Pharmaceutical Group

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory and metabolic diseases. Its pipeline includes therapies for chronic gout and non-alcoholic steatohepatitis (NASH).

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Atom Bioscience is a clinical-stage biotechnology company focused on developing innovative treatments for inflammatory and metabolic diseases. Its pipeline includes therapies for chronic gout and non-alcoholic steatohepatitis (NASH).

Elicio Therapeutics, a biotechnology company based in Cambridge, Massachusetts, specializes in developing innovative immunotherapies for treating aggressive cancers. Its proprietary Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, amplifying the body's immune response against cancer.

Yizun Biotechnology is a cutting-edge immune cell therapy company that has developed many unique platform technologies, including solid tumor treatment and allogeneic universal cell therapy.

Livzon Mabpharm is a Chinese biotechnology company focused on the development, manufacture, and sale of antibody-based drugs.

LungLife AI, Inc. is a clinical diagnostics company based in Thousand Oaks, California, specializing in the early detection and management of lung cancer through the molecular analysis of cancer biomarkers in blood. The company utilizes machine learning and artificial intelligence to enhance the accuracy and efficiency of cancer diagnosis and treatment. LungLife AI offers a range of products, including the LiquidBiopsy platform for isolating rare cells from blood samples and the Everest software for sequence analysis. Additionally, it provides CLIA/CAP lab services, such as the ClearID test for identifying targetable DNA mutations and the NK Vue test for monitoring immune system health. The company's offerings aim to improve treatment stratification and monitoring across all stages of lung cancer. LungLife AI was founded in 2006 and was formerly known as Cynvenio Biosystems, Inc. It also maintains a strategic collaboration with the Institute of Regional Health Research.

Imexpharm is a Vietnamese pharmaceutical company that manufactures, processes, trades, imports, and exports pharmaceutical products for domestic and international markets. Its product range includes oral and injectable antibiotics, medicines for digestion, the central nervous system, cardiovascular, diabetes, and musculoskeletal conditions, as well as respiratory, analgesic and anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic therapies, along with vitamins and minerals. The company also handles the import and export of pharmaceutical products, medical equipment and supplies, chemicals, materials used in medicine manufacturing and packaging, and sterilization or disinfection chemicals. Founded in 1977, Imexpharm is headquartered in Cao Lanh, Vietnam.